Non-homologous use of adipose-derived cell and tissue therapies: Osteoarthritis as a case study

Trivia Frazier, Keith March, Jaime R. Garza, Bruce A. Bunnell, Kevin F. Darr, Emma Rogers, Katie Hamel, Jeffrey M. Gimble

Research output: Contribution to journalReview articlepeer-review

Abstract

Adipose tissue is widely recognized as an abundant and accessible human tissue that serves as a source of cells and extracellular matrix scaffolds for regenerative surgical applications. Increasingly, orthopedic surgeons are turning to adipose tissue as a resource in their treatment of osteoarthritis and related conditions. In the U.S., the regulatory landscape governing the orthopedic surgical utilization of autologous and allogeneic adipose tissue remains complex. This manuscript reviews the Food and Drug Administration's nomenclature and guidance regarding adipose tissue products. Additionally, it surveys recent pre-clinical and clinical trial literature relating to the application of adipose-derived cells and tissues in the treatment of osteoarthritis.

Original languageEnglish
Article number101601
JournalBone Reports
Volume17
DOIs
StatePublished - Dec 2022

Keywords

  • Adipose
  • Microfragmented fat
  • Osteoarthritis
  • Regenerative medicine
  • Regulatory agency
  • Stromal/stem cells

Fingerprint

Dive into the research topics of 'Non-homologous use of adipose-derived cell and tissue therapies: Osteoarthritis as a case study'. Together they form a unique fingerprint.

Cite this